Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijs.12073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.
Front Pharmacol
November 2024
Department of Pharmacy, Shanxi Cardiovascular Disease Hospital, Taiyuan, Shanxi, China.
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the variation in acute pancreatitis (AP) risk among different GLP-1 RAs. Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
View Article and Find Full Text PDFA wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models.
Sci Transl Med
November 2024
State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
The maintenance of stable plasma drug concentrations within a therapeutic window can be critical for drug efficacy. Here, we developed a wearable osmotic microneedle (OMN) patch to support sustained drug dosing for at least 24 hours without the use of electronic components. The OMN patch uses an osmotic pressure driving force to deliver drug solution into the skin through three hollow microneedles with diameters of less than 200 micrometers.
View Article and Find Full Text PDFEffects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
Postgrad Med J
November 2024
Department of Cardiology, Shandong University of Traditional Chinese Medicine, Second Affiliated Hospital, No. 1 Jingba Road Jinan, Shandong Province 250001, China.
Background: Currently, there is no relevant study comparing sodium-dependent glucose transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase inhibitor (DPP4i) head to head to evaluate their comprehensive impact on heart failure patients.
Methods: We conducted a comprehensive literature search across multiple databases. Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Discovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.
Hum Exp Toxicol
October 2024
Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Aluminum phosphide (AlP) is a dangerous chemical that can cause death by harming heart cells, and there aren't any approved medicines to treat it yet.
- Researchers are looking into different ways to lessen the harmful effects of AlP poisoning, including improving heart function and using various compounds.
- Some treatments like fresh red blood cell transfusion and certain medicines show promise in helping patients, but more research is needed to confirm the best ways to treat AlP poisoning.
Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study.
Diabetes Metab Syndr
September 2024
Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, National Diabetes, Obesity and Cholesterol Foundation (N-DOC), Diabetes Foundation (India) (DFI) India, India. Electronic address:
Article Synopsis
- Acute pancreatitis (AP) is a serious health issue that can recur, especially among individuals with type 2 diabetes (T2D) or obesity; this study examines how GLP-1 receptor agonists (GLP-1RAs) impact the recurrence risk of AP.
- Researchers analyzed data from over 258,000 patients with T2D or obesity and a history of AP, finding that those who used GLP-1RAs had significantly lower recurrence rates compared to non-users.
- Specifically, Semaglutide and Tirzepatide users showed the best outcomes, with Tirzepatide presenting the lowest recurrence risk at 6.2%, suggesting the need for
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!